Efficacy of Janus kinase inhibitors in rheumatoid arthritis

被引：0
|
作者：
Camille Langbour
Jessica Rene
Philippe Goupille
Guillermo Carvajal Alegria
机构：
[1] CHRU de Tours,Service de Rhumatologie
[2] Université de Tours,undefined
来源：
Inflammation Research | 2023年 / 72卷
关键词：
Tofacitinib; Upadacitinib; Baricitinib; Filgotinib; Rheumatoid arthritis; Efficacy; Predictive factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1121 / 1132
页数：11
相关论文
共 50 条
  • [31] Selective Janus kinase inhibitors: Promising drugs for rheumatoid arthritis
    Zanwar, Abhishek
    Aggarwal, Amita
    NATIONAL MEDICAL JOURNAL OF INDIA, 2019, 32 (02) : 96 - +
  • [32] Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study
    Nakayama, Yoichi
    Onishi, Akira
    Yamamoto, Wataru
    Yoshikawa, Ayaka
    Shiba, Hideyuki
    Yoshida, Naofumi
    Son, Yonsu
    Shirasugi, Iku
    Maeda, Toshihisa
    Katsushima, Masao
    Hashimoto, Motomu
    Etani, Yuki
    Itami, Tetsu
    Nozaki, Yuji
    Onizawa, Hideo
    Fujii, Takayuki
    Murakami, Kosaku
    Murata, Koichi
    Tanaka, Masao
    Matsuda, Shuichi
    Morinobu, Akio
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [33] Crucial safety issues on Janus kinase inhibitors in rheumatoid arthritis might be associated with the lack of LDL-cholesterol management: a reasoned literature analysis
    Corrao, Salvatore
    INTERNAL AND EMERGENCY MEDICINE, 2023, 18 (08) : 2157 - 2161
  • [34] A novel treatment for psoriatic arthritis: Janus kinase inhibitors
    Chen, Miao
    Dai, Sheng-Ming
    CHINESE MEDICAL JOURNAL, 2020, 133 (08) : 959 - 967
  • [35] Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
    Shunsuke Mori
    Fumihiko Ogata
    Ryusuke Tsunoda
    Clinical Rheumatology, 2021, 40 : 4457 - 4471
  • [36] Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
    Taylor, Peter C.
    RHEUMATOLOGY, 2019, 58 : 17 - 26
  • [37] Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis
    Hayashi, Shinya
    Nakano, Naoki
    Tsubosaka, Masanori
    Kamenaga, Tomoyuki
    Kuroda, Yuichi
    Matsumoto, Tomoyuki
    Yamada, Hirotaka
    Nishimra, Keisuke
    Ueda, Yo
    Saegusa, Jun
    Kuroda, Ryosuke
    CLINICAL RHEUMATOLOGY, 2024, 43 (11) : 3285 - 3292
  • [38] Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
    Mori, Shunsuke
    Ogata, Fumihiko
    Tsunoda, Ryusuke
    CLINICAL RHEUMATOLOGY, 2021, 40 (11) : 4457 - 4471
  • [39] Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
    Dowty, Martin E.
    Lin, Tsung H.
    Jesson, Michael I.
    Hegen, Martin
    Martin, David A.
    Katkade, Vaibhav
    Menon, Sujatha
    Telliez, Jean-Baptiste
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019, 7 (06):
  • [40] Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
    Kotyla, Przemyslaw J.
    Islam, Md Asiful
    Engelmann, Malgorzata
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (19) : 1 - 17
12345